Ang SYL, et al. - Using an ethnically diverse sample, researchers assessed the incidences of O⁶-methylguanine-DNA-methyltransferase (MGMT) promoter methylation, 1p19q co-deletion, isocitrate dehydrogenase (IDH) gene mutations, and inactivating mutations of alpha-thalassemia/mental retardation syndrome X-linked (ATRX) in high-grade gliomas. They studied data from 181 patients (including 56 with grade III gliomas, 125 with grade IV gliomas) who were surgically treated for high-grade gliomas from January 2013 to March 2017 at their institution. They identified MGMT promoter methylation, 1p19q co-deletion, IDH1 mutation, and ATRX loss in 55%, 41%, 35%, and in none, respectively, in the grade III group. In the grade IV group, MGMT promoter methylation, 1p19q co-deletion, IDH1 mutation, and ATRX loss were detected in 30%, 2%, 15%, and in 8%, respectively. In contrast to globally reported rates, comparable incidences were reported for MGMT promoter methylation and IDH1 mutation in this study, however, incidences of 1p19q co-deletion and ATRX loss appeared to be lower in this cohort. Increased overall survival related to MGMT promoter methylation was reported in this cohort, and the likely utility of MGMT promoter methylation as a favorable prognostic factor was suggested.